weight loss

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic face heightened health risks during the current heat wave. The drugs can contribute to dehydration, and patients may not feel thirsty or may experience nausea and vomiting, making it harder to stay hydrated. Medical experts are advising users to drink water regularly, avoid excessive heat, and seek medical attention if they develop dizziness or other symptoms of dehydration.

Mexico's national team lost to the United States, a result drawing wide attention across Mexico, Spain and the US. ESPN México reports that coach Jaime Lozano-era analyst Márquez's project remains unaffected by the defeat, arguing the loss does not undermine the team's longer-term development plan despite the rivalry's emotional weight for fans.

A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.

GLP-1 medications such as Ozempic and Wegovy are being discussed as a new approach to weight loss, moving beyond diet and exercise as the standard advice. Johns Hopkins University is among the institutions weighing in on how these drugs work and what their rise means for obesity treatment. The conversation centers on effectiveness, costs, and how widely these drugs will change care.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are being linked to changes in sleep health, with researchers examining how significant weight loss affects sleep apnoea and other sleep disorders. The trend is prompting sleep medicine specialists to rethink diagnosis rates, treatment demand and how therapies like CPAP may be used as more patients take these medications.

An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.

A functional medicine expert is cautioning that high doses of GLP-1 weight-loss and diabetes drugs may affect more than appetite, potentially disrupting other bodily processes beyond food cravings. The warning, reported by Fox News, adds to ongoing debate about the safety and long-term effects of medications such as Ozempic and Wegovy as their use continues to expand.

Users of Ozempic and similar GLP-1 weight-loss and diabetes drugs are reporting nail problems, adding to previously reported side effects such as hair loss. The new complaints suggest the medications may affect more of the body than initially understood, prompting discussion among patients and clinicians about the wider physical effects of the increasingly popular drugs.

Young people taking GLP-1 receptor agonists, the class of drugs that includes Ozempic and Wegovy, are showing nutritional deficiencies, according to coverage in medical news outlets. The reports add to ongoing scrutiny of the drugs' safety in children and adolescents, with clinicians urged to monitor patients' nutrient intake while on the medications.

New research suggests that people who lose the same amount of weight can experience very different health outcomes, with identical weight loss not producing the same metabolic or cardiovascular benefits in everyone. The findings point to individual differences in how the body responds to weight loss and could affect how doctors evaluate diet success beyond the scale.

The municipal council of Katwijk in the Netherlands has approved a building plan for a large American diet pill factory, reportedly belonging to pharmaceutical company Eli Lilly. The facility would produce popular weight-loss injections such as Zepbound or Mounjaro, and the decision is drawing local attention over its scale and impact on the region.

Italian health coverage is converging on blood sugar and cardiovascular risk. New research shows stress can send glucose test results sharply higher, while commentators stress that GLP-1 weight-loss drugs are not enough without proper nutrition education. It comes as the European Commission launches its first EU Screening Week from Milan and issues new recommendations to member states, with cardiovascular diseases causing 1.7 million deaths a year in Europe.

New research suggests tirzepatide, the weight-loss and diabetes drug sold as Mounjaro and Zepbound, may activate brown fat, a type of tissue that burns calories to generate heat. If confirmed, the finding could help explain the drug's effectiveness and open new avenues in obesity treatment. Coverage is so far limited, with fitness outlets picking up the claim and experts urging caution until results are published in full.

Novo Nordisk has received approval in Singapore for Wegovy as the first treatment for MASH, a liver disease involving fibrosis. It marks a new indication for the weight-loss drug beyond obesity and diabetes. Attention centres on how semaglutide could expand into treating fatty liver disease globally.

Nutritionist Ayesha Nasir has released an October diet plan promising viewers a chance to finally lose weight. The plan is drawing significant attention, with over 143,000 likes, as audiences seek seasonal guidance on shedding pounds before the end of the year. Followers of nutrition content are discussing the regimen and its weight-loss claims.

Brazilian health outlets are publishing advice on managing blood glucose levels before breakfast, recommending simple morning habits to add to daily routines. The topic coincides with renewed attention on weight-loss injections, as a study on retatrutide showed participants losing up to 23.4% of their body weight, keeping blood sugar and metabolic health in the public conversation.

Tirzepatide, the injectable drug sold as Mounjaro, is being discussed after a Guardian report described it as the 'Godzilla' of weight-loss drugs, saying it could provide other important health benefits beyond shedding pounds. Researchers are examining whether the medication, which targets two gut hormones, may also improve conditions such as heart and metabolic disease.

Novo Nordisk is lowering the price of its weight-loss drug Wegovy by 20 percent in Sweden, according to multiple Swedish business and news outlets. The move comes as GLP-1 medicines, once marketed primarily as obesity treatments for patients, are increasingly described in industry coverage as lifestyle drugs competing for customers, intensifying pressure on pricing.

A major clinical trial has found that diet drinks are just as effective as water for weight loss, challenging a common belief that artificially sweetened beverages undermine dieting efforts. The results suggest people trying to lose weight need not avoid low- or no-calorie drinks, a finding likely to fuel ongoing debate among nutrition experts about the role of sweeteners in health and weight management.

A Medium essay titled 'On Being Fat' by author J. Cafesin is circulating on social media, tagged across health, obesity, dieting and exercise topics. The piece addresses overweight, denial and the realities of weight loss, and is being shared amid ongoing holiday-season discussion about food, fitness and body health.

New coverage suggests diet drinks may be just as effective as water for weight loss, positioning them as a practical alternative to sugar-sweetened beverages. The finding challenges the common assumption that artificially sweetened drinks hinder dieting efforts and could influence guidance for people trying to cut calories while still consuming flavoured drinks.

New Zealand dairy giant Fonterra is moving to serve the nutritional needs of people taking weight-loss medications such as GLP-1 drugs, which reduce appetite and can leave users short of protein and key nutrients. The company is positioning high-protein dairy products to fill that gap, tapping into one of the fastest-growing trends in global food and health.

A Washington Post advice column by Eric addresses a reader whose illness caused weight loss, only for them to face shaming over being too skinny. The columnist responds to the insensitivity of commenting on someone's body during illness. Advice columns like this resonate widely because body-shaming stories strike a chord, and readers often share their own experiences of thoughtless remarks about health and appearance.

A Hindi-language diet plan promising rapid weight loss is drawing large audiences online. The plan promotes a quick fat-loss diet aimed at people looking to shed weight fast, and viewers are engaging heavily with the guidance. As with any rapid weight-loss diet, nutrition experts generally caution that sustainable results come from balanced eating rather than extreme short-term plans.

A memorial event in the Chicago area has been held to honor victims of murder, with participants reflecting on grief that endures long after the loss. Coverage of the gathering carries the message that the pain for surviving families 'cannot be erased,' underscoring the emotional weight of remembering those killed.